Inhibition of FSP1: A new strategy for the treatment of tumors (Review).

IF 3.8 3区 医学 Q2 ONCOLOGY Oncology reports Pub Date : 2024-08-01 Epub Date: 2024-06-28 DOI:10.3892/or.2024.8764
Qiangfang Dai, Xiaoli Wei, Jumei Zhao, Die Zhang, Yidan Luo, Yue Yang, Yang Xiang, Xiaolong Liu
{"title":"Inhibition of FSP1: A new strategy for the treatment of tumors (Review).","authors":"Qiangfang Dai, Xiaoli Wei, Jumei Zhao, Die Zhang, Yidan Luo, Yue Yang, Yang Xiang, Xiaolong Liu","doi":"10.3892/or.2024.8764","DOIUrl":null,"url":null,"abstract":"<p><p>Ferroptosis, a regulated form of cell death, is intricately linked to iron‑dependent lipid peroxidation. Recent evidence strongly supports the induction of ferroptosis as a promising strategy for treating cancers resistant to conventional therapies. A key player in ferroptosis regulation is ferroptosis suppressor protein 1 (FSP1), which promotes cancer cell resistance by promoting the production of the antioxidant form of coenzyme Q10. Of note, FSP1 confers resistance to ferroptosis independently of the glutathione (GSH) and glutathione peroxidase‑4 pathway. Therefore, targeting FSP1 to weaken its inhibition of ferroptosis may be a viable strategy for treating refractory cancer. This review aims to clarify the molecular mechanisms underlying ferroptosis, the specific pathway by which FSP1 suppresses ferroptosis and the effect of FSP1 inhibitors on cancer cells.</p>","PeriodicalId":19527,"journal":{"name":"Oncology reports","volume":null,"pages":null},"PeriodicalIF":3.8000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11228423/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3892/or.2024.8764","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/28 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Ferroptosis, a regulated form of cell death, is intricately linked to iron‑dependent lipid peroxidation. Recent evidence strongly supports the induction of ferroptosis as a promising strategy for treating cancers resistant to conventional therapies. A key player in ferroptosis regulation is ferroptosis suppressor protein 1 (FSP1), which promotes cancer cell resistance by promoting the production of the antioxidant form of coenzyme Q10. Of note, FSP1 confers resistance to ferroptosis independently of the glutathione (GSH) and glutathione peroxidase‑4 pathway. Therefore, targeting FSP1 to weaken its inhibition of ferroptosis may be a viable strategy for treating refractory cancer. This review aims to clarify the molecular mechanisms underlying ferroptosis, the specific pathway by which FSP1 suppresses ferroptosis and the effect of FSP1 inhibitors on cancer cells.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
抑制 FSP1:治疗肿瘤的新策略(综述)。
铁变态反应是一种受调控的细胞死亡形式,与依赖铁的脂质过氧化反应密切相关。最近的证据有力地证明,诱导铁氧化是治疗对传统疗法产生抗药性的癌症的一种有前途的策略。铁氧化抑制蛋白1(FSP1)是铁氧化调节的一个关键角色,它通过促进辅酶Q10抗氧化形式的产生来增强癌细胞的抵抗力。值得注意的是,FSP1 可独立于谷胱甘肽(GSH)和谷胱甘肽过氧化物酶-4 途径而产生对铁变态反应的抵抗力。因此,靶向 FSP1 以削弱其对铁蛋白沉积的抑制作用可能是治疗难治性癌症的一种可行策略。本综述旨在阐明铁突变的分子机制、FSP1抑制铁突变的具体途径以及FSP1抑制剂对癌细胞的影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Oncology reports
Oncology reports 医学-肿瘤学
CiteScore
8.50
自引率
2.40%
发文量
187
审稿时长
3 months
期刊介绍: Oncology Reports is a monthly, peer-reviewed journal devoted to the publication of high quality original studies and reviews concerning a broad and comprehensive view of fundamental and applied research in oncology, focusing on carcinogenesis, metastasis and epidemiology.
期刊最新文献
[Retracted] hsa‑miR‑212 modulates the radiosensitivity of glioma cells by targeting BRCA1. Progress of research on γδ T cells in colorectal cancer (Review). [Corrigendum] Omi/HtrA2 pro-apoptotic marker differs in various hepatocellular carcinoma cell lines owing to ped/pea-15 expression level. [Retracted] miRNA‑490‑3p promotes the metastatic progression of invasive ductal carcinoma. Antitumor activities of anti‑CD44 monoclonal antibodies in mouse xenograft models of esophageal cancer.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1